Historique
Auteur R. McDONALD
Documents disponibles écrits par cet auteur (7)
Ajouter le résultat à votre sélection Affiner la rechercheNouveauté
Background and Aims: Fatal outcome of opioid overdose, once detected, is preventable through timely administration of the antidote naloxone. Take-home naloxone provision directly to opioid users for emergency use has been implemented recently in[...]![Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? [For debate]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=77057)
J. STRANG ; R. McDONALD ; B. TAS ; E. DAY | 2016
Dans Addiction (Vol.111, n°4, April 2016) Article : PériodiqueContext: Take-home naloxone is increasingly provided to prevent heroin overdose deaths. Naloxone 0.4-2.0 mg is licensed for use by injection. Some clinicians supply improvised nasal naloxone kits (outside lisenced approval). Is this acceptable? [...]
J. STRANG ; R. McDONALD ; A. ALQURSHI ; P. ROYALL ; D. TAYLOR ; B. FORBES | 2016
Dans Drug and Alcohol Dependence (Vol.163, June 2016) Article : PériodiqueIntroduction: Deaths from opioid overdose can be prevented through administration of the antagonist naloxone, which has been licensed for injection since the 1970s. To support wider availability of naloxone in community settings, novel non-injec[...]
A. CHENG ; R. BADOLATO ; A. SEGOSHI ; R. McDONALD ; M. MALONE ; K. VASUDEVAN ; B. BADIEI ; A. SUGARMAN ; R. MACDONALD ; J. MANGAT ; J. GIFTOS ; J. D. LEE ; B. TOFIGHI | 2022
Dans Addiction Science and Clinical Practice (Vol.17, 2022) Article : PériodiqueBackground: Extended-release buprenorphine (XRB) offers a novel approach to sustained monthly treatment for people who use opioids in criminal justice settings (CJS). This study explores the experiences of adults receiving XRB as a jail-to-commu[...]
This publication examines the case for distributing naloxone, an emergency medication, to people who inject opioids such as heroin and to others who might witness an opioid overdose. Through its capacity to reverse opioid overdose, naloxone can [...]
R. McDONALD ; S. BREIDAHL ; K. ABEL-OLLO ; S. AKHTAR ; T. CLAUSEN ; E. DAY ; M. KELLEHER ; A. McAULEY ; H. PETERSEN ; M. SEFRANEK ; H. THIESEN ; J. STRANG | 2022
Dans European Addiction Research (Vol.28, n°3, May 2022) Article : PériodiqueBACKGROUND: Injectable naloxone is already provided as take-home naloxone (THN), and new concentrated intranasal naloxone is now being introduced in Europe. Despite evidence of the effectiveness and cost-effectiveness of THN, little is known abo[...]
R. McDONALD ; N. D. CAMPBELL ; J. STRANG | 2017
Dans Drug and Alcohol Dependence (Vol.178, September 2017) Article : PériodiqueBackground: Opioid overdose is a major cause of mortality, but injury and fatal outcomes can be prevented by timely administration of the opioid antagonist naloxone. Pre-provision of naloxone to opioid users and family members (take-home naloxon[...]
